Drug Profile
Research programme: parenteral therapeutics - Eagle/Curia
Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Eagle Pharmaceuticals
- Developer Curia; Eagle Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Unspecified in USA
- 11 Jan 2016 AMRI and Eagle pharmaceuticals agree develop, manufacture and market parenteral drug products in USA